We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TERIPARATIDE RBX/ RITOSA/ TERIPARATIDE SUN (Sun Pharma ANZ Pty Ltd)
Product name
TERIPARATIDE RBX/ RITOSA/ TERIPARATIDE SUN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
126 (255 working days)
Active ingredients
Teriparatide
Registration type
NCE/NBE
Indication
TERIPARATIDE RBX/ RITOSA/ TERIPARATIDE SUN is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.
Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.